<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00325130</url>
  </required_header>
  <id_info>
    <org_study_id>V501-025</org_study_id>
    <secondary_id>2005_092</secondary_id>
    <nct_id>NCT00325130</nct_id>
  </id_info>
  <brief_title>Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)</brief_title>
  <official_title>An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V501 Given Concomitantly With Menactra™ and ADACEL™ in Healthy Adolescents 11-17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from this study are expected to demonstrate that V501 (Human Papillomavirus (HPV) [Types
      6, 11, 16, 18] Recombinant Vaccine) , when administered concomitantly with a combined
      diphtheria, tetanus, pertussis (Tdap) vaccine and a meningococcal conjugate vaccine in
      adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity
      of the concomitant vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 (7 Months)</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 24 mMU/mL) by Week 4 Postdose 3 (7 Months)</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup A One Month Postvaccination (Week 4 Postdose 1) With Menactra™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup C One Month Postvaccination (Week 4 Postdose 1) With Menactra™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup W-135 One Month Postvaccination (Week 4 Postdose 1) With Menactra™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup Y One Month Postvaccination With Menactra™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers (Diphtheria ≥ 0.1 IU/mL) to Diphtheria One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 (7 Months) of GARDASIL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 (7 Months) of GARDASIL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 (7 Months) of GARDASIL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 (7 Months) of GARDASIL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis Anti-Pertussis Toxin (Anti-PT) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis Anti-Filamentous Hemagglutinin) (Anti-FHA) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis Anti Pertactin (Anti-PRN) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) for Pertussis Anti-Fimbrial Agglutinogens 2/3 (Anti-FIM) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</measure>
    <time_frame>7 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptable Safety Profile</measure>
    <time_frame>15 days post injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1042</enrollment>
  <condition>Neoplasms, Glandular and Epithelial</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Whooping Cough</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-concomitant administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine</intervention_name>
    <description>Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a
0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Gardasil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Menactra™ (Concomitant)</intervention_name>
    <description>A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Adacel™ (Concomitant)</intervention_name>
    <description>a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Menactra™ (Non-concomitant)</intervention_name>
    <description>A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Adacel™</intervention_name>
    <description>A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be healthy boys or girls, 11-17 years of age

          -  Must be a virgin with no intention of becoming sexually active during the study period

          -  Must have been properly vaccinated against diphtheria, tetanus and pertussis

        Exclusion Criteria:

          -  Must not have received a vaccine against diphtheria, tetanus and pertussis in the past
             5 years

          -  Must not have received any prior human papillomavirus (HPV) vaccine or meningococcal
             vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, Radley D, Sings HL, Haupt RM, Garner EI; Protocol 025 Investigators. Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics. 2010 Jun;125(6):1142-51. doi: 10.1542/peds.2009-2336. Epub 2010 May 3.</citation>
    <PMID>20439595</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2006</study_first_submitted>
  <study_first_submitted_qc>May 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2006</study_first_posted>
  <results_first_submitted>May 19, 2009</results_first_submitted>
  <results_first_submitted_qc>May 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2009</results_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Concomitant Administration</title>
          <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
        </group>
        <group group_id="P2">
          <title>Non-concomitant Administration</title>
          <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="518"/>
                <participants group_id="P2" count="524"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Discontinued for Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Concomitant Administration</title>
          <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
        </group>
        <group group_id="B2">
          <title>Non-concomitant Administration</title>
          <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="518"/>
            <count group_id="B2" value="524"/>
            <count group_id="B3" value="1042"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.5" spread="1.84"/>
                    <measurement group_id="B2" value="12.7" spread="1.90"/>
                    <measurement group_id="B3" value="12.6" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>9 Years of Age and Under</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 to 17 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="518"/>
                    <measurement group_id="B2" value="524"/>
                    <measurement group_id="B3" value="1042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 17 Years of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="340"/>
                    <measurement group_id="B3" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="406"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceptable Safety Profile</title>
        <time_frame>15 days post injection</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418"/>
                    <measurement group_id="O2" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 24 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 24 mMU/mL) by Week 4 Postdose 3 (7 Months)</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="421"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                    <measurement group_id="O2" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -5%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup A One Month Postvaccination (Week 4 Postdose 1) With Menactra™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup A One Month Postvaccination (Week 4 Postdose 1) With Menactra™</title>
          <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup C One Month Postvaccination (Week 4 Postdose 1) With Menactra™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup C One Month Postvaccination (Week 4 Postdose 1) With Menactra™</title>
          <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup W-135 One Month Postvaccination (Week 4 Postdose 1) With Menactra™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup W-135 One Month Postvaccination (Week 4 Postdose 1) With Menactra™</title>
          <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="446"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                    <measurement group_id="O2" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup Y One Month Postvaccination With Menactra™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup Y One Month Postvaccination With Menactra™</title>
          <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                    <measurement group_id="O2" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers (Diphtheria ≥ 0.1 IU/mL) to Diphtheria One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved Acceptable Levels of Titers (Diphtheria ≥ 0.1 IU/mL) to Diphtheria One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
          <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397"/>
                    <measurement group_id="O2" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
          <population>Per-protocol population: subjects must have no major protocol violations and must have post-vaccination data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="398"/>
                <count group_id="O2" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in seroconversion rates (concomitant group -
nonconcomitant group) must be greater than -10%</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>Miettinen &amp; Nurminen</method>
            <method_desc>Miettinen &amp; Nurminen method for difference in proportions, Stat Med 1985;4:213-26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1349.3" lower_limit="1189.7" upper_limit="1530.3"/>
                    <measurement group_id="O2" value="1340.8" lower_limit="1181.6" upper_limit="1521.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have post-vaccination data.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1609.6" lower_limit="1469.9" upper_limit="1762.6"/>
                    <measurement group_id="O2" value="1513.7" lower_limit="1381.8" upper_limit="1658.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have
post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
          <population>Per-protocol population: subjects must
have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have
post-vaccination data.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="421"/>
                <count group_id="O2" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7203.0" lower_limit="6448.0" upper_limit="8046.4"/>
                    <measurement group_id="O2" value="7370.0" lower_limit="6593.6" upper_limit="8237.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have
post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 (7 Months) of GARDASIL™</title>
          <population>Per-protocol population: subjects must
have no major protocol violations, must be seronegative at baseline to the relevant HPV type, and must have
post-vaccination data.</population>
          <units>mMU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="421"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1270.2" lower_limit="1128.9" upper_limit="1429.1"/>
                    <measurement group_id="O2" value="1425.3" lower_limit="1265.7" upper_limit="1605.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.5.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis Anti-Pertussis Toxin (Anti-PT) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Pertussis Anti-Pertussis Toxin (Anti-PT) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
          <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
          <units>ELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="16.9" upper_limit="20.2"/>
                    <measurement group_id="O2" value="19.3" lower_limit="17.5" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis Anti-Filamentous Hemagglutinin) (Anti-FHA) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Pertussis Anti-Filamentous Hemagglutinin) (Anti-FHA) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
          <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
          <units>ELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.5" lower_limit="122.4" upper_limit="143.4"/>
                    <measurement group_id="O2" value="150.9" lower_limit="138.9" upper_limit="164.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis Anti Pertactin (Anti-PRN) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Pertussis Anti Pertactin (Anti-PRN) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
          <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
          <units>ELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.6" lower_limit="229.8" upper_limit="279.9"/>
                    <measurement group_id="O2" value="274.2" lower_limit="274.2" upper_limit="304.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) for Pertussis Anti-Fimbrial Agglutinogens 2/3 (Anti-FIM) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
        <time_frame>7 Months</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Administration</title>
            <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Administration</title>
            <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) for Pertussis Anti-Fimbrial Agglutinogens 2/3 (Anti-FIM) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™</title>
          <population>Per-protocol population: subjects must
have no major protocol violations and must have post-vaccination data.</population>
          <units>ELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703.0" lower_limit="609.9" upper_limit="810.2"/>
                    <measurement group_id="O2" value="611.2" lower_limit="526.4" upper_limit="709.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ratio of GMTs (concomitant group / nonconcomitant group)
must be greater than 0.67.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Since p&lt;0.05, the hypothesis of noninferiority is accepted for this outcome.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA on natural log titer with fixed effects for region, vaccination group and their interaction.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Concomitant Administration</title>
          <description>Concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
        </group>
        <group group_id="E2">
          <title>Non-concomitant Administration</title>
          <description>Non-concomitant administration of quadrivalent HPV vaccine and Menactra™ and ADACEL™</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Parotidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="498"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="475"/>
                <counts group_id="E2" subjects_affected="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="520"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain quadrivalent HPV Vaccine postvaccination 1</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling HPV Vaccine postvaccination 1</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema qHPV Vaccine (postvaccination 2)</sub_title>
                <description>qHPV = quadrivalent HPV Vaccine</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Injection Site Pain qHPV Vaccine (postvaccination 2)</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema qHPV Vaccine (postvaccination 3)</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Injection Site Pain qHPV Vaccine (postvaccination 3)</sub_title>
                <counts group_id="E1" subjects_affected="253" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling qHPV Vaccine (postvaccination 3)</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="503"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema ADACEL™ + Menactra™</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Injection Site Pain ADACEL™ + Menactra™</sub_title>
                <counts group_id="E1" subjects_affected="421" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="303" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling ADACEL™ + Menactra™</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema qHPV Vaccine (post-vaccination 1)</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling qHPV Vaccine (post-vaccination 2)</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="506"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="492"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising ADACEL™ + Menactra™</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="514"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="520"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache Systemic Clinical</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="520"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="498"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="520"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="498"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

